THE NEED FOR SURVEILLANCE AND LIMITATIONS OF CURRENT METHODSTunneled and nontunneled central venous catheters (CVCs) are necessary to facilitate treatment of many hematologic disorders, but catheter-related bloodstream infections (CR-BSIs) are an important cause of morbidity and mortality, and may lead to interruptions in planned therapy for malignancy or increases in length of hospital stay. In immunocompromised populations with neoplastic disease, risks for infection are not uniform, 1 and increased risk for bloodstream infections in patients with hematological malignancy may be related to the underlying malignancy, chemotherapy-induced granulocytopenia, breaches in skin or mucosal integrity, or invasive procedures.
2,3Standardized surveillance measures have not been used to assess interventions with potential impact on the epidemiology of CR-BSIs. For example, widespread use of antibiotic lock therapy,